AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates with manageable safety profiles.

The latest lung cancer data arrives during a strong run for AbbVie, with a 24.32% 90 day share price return and a 31.62% 1 year total shareholder return suggesting that momentum has been building.

If this lung cancer update has you looking more broadly at healthcare opportunities, it could be a good time to check out other potential growth stories through our screener of 41 healthcare AI stocks

AbbVie’s lung cancer update arrives after a powerful run in the stock. The key issue now is whether recent gains have already priced in most of the opportunity, or if the current valuation still leaves clear upside on the table.

Most Popular Narrative: 3.1% Undervalued

AbbVie last closed at $264.96 compared with a widely followed fair value estimate of about $273 per share, which frames how some investors view the lung cancer data in the context of the broader story.

Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top line revenue growth and mitigate the impact of Humira's LOE.

Want to see what really sits behind that fair value for AbbVie? The narrative leans on ambitious revenue expansion, rising margins and a richer earnings multiple. Curious which assumptions matter most?

This widely followed framework uses a discount rate of 7.64% and ties AbbVie’s valuation to expectations around future growth in immunology, neuroscience and newer oncology assets. It also bakes in views on how long elevated profitability can be maintained as the portfolio shifts away from legacy products and as deals like Apogee are absorbed into the model.

Result: Fair Value of $273.39 (UNDERVALUED)

However, there are still clear risks to the AbbVie story if newer therapies underperform in the clinic or if drug pricing reforms compress margins faster than expected.

Another View on AbbVie’s Valuation

The fair value narrative for AbbVie leans on future earnings and multiples that could support the current share price. Yet on today’s numbers, the P/E ratio of 74.7x is well above the US Biotechs industry at 17.4x and peers at 29.1x, and is also higher than the 39.3x fair ratio estimate.

That gap suggests investors are already paying a steep premium for AbbVie, which raises the risk that any disappointment in execution or lung cancer data could hit the share price harder than for cheaper stocks. The question is whether you think the current premium is justified, or if the market could move closer to that fair ratio over time.

Next Steps

With AbbVie drawing such mixed reactions, it helps to move fast, review the underlying numbers yourself and then decide what really matters. To balance the optimism around rewards with the concerns about risks, start by checking the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond AbbVie?

If AbbVie has sharpened your focus on where to put fresh capital next, consider scanning for other potential opportunities with clear, data driven filters.

• Target resilient income by reviewing companies in the 12 dividend fortresses that aim to combine higher yields with consistency.
• Hunt for quality at a discount by reviewing the 48 high quality undervalued stocks and see which stocks currently trade below their fundamentals.
• Prioritize resilience and capital preservation by scanning the 75 resilient stocks with low risk scores so you are not the last to spot lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.